Posted by Michael Wonder on 21 Nov 2023
Ascendis Pharma announces European Commission approval of Yorvipath (palopegteriparatide) for the treatment of adults with chronic hypoparathyroidism
20 November 2023 - Ascendis plans its first EU launch of Yorvipath in Germany in January 2024.
Ascendis Pharma today announced that the European Commission has granted marketing authorisation for Yorvipath (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.
